ImmuPharma (LON:IMM) Trading Up 9.5% - Should You Buy?

Key Points

• ImmuPharma plc shares surged by 9.5% to GBX 12.10 ($0.16) during mid-day trading, significantly increasing trading volume by 176% compared to the average daily volume.
• The company reported a negative EPS of GBX (0.38) for the last quarter, with analysts predicting a current year EPS of -339.00.
• ImmuPharma specializes in developing peptide-based therapeutics for autoimmune diseases, with its lead program being a treatment for Lupus.

ImmuPharma plc (LON:IMM - Get Free Report) shares were up 9.5% during mid-day trading on Tuesday . The company traded as high as GBX 14.20 ($0.19) and last traded at GBX 12.10 ($0.16). Approximately 23,646,498 shares were traded during trading, an increase of 176% from the average daily volume of 8,583,096 shares. The stock had previously closed at GBX 11.05 ($0.15).

ImmuPharma Trading Up 9.5%

The firm has a market capitalization of £60.47 million, a PE ratio of -1,359.55 and a beta of 1.53. The stock has a 50 day simple moving average of GBX 4.66 and a 200 day simple moving average of GBX 3.39.

ImmuPharma (LON:IMM - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported GBX (0.38) EPS for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities analysts anticipate that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.